Selvigaltin is under clinical development by Galecto and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Selvigaltin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Selvigaltin overview

Selvigaltin is under development for the treatment of liver cirrhosis, decompensated cirrhosis (Child-Pugh B), metastatic melanoma, head and neck squamous cell carcinoma, non-alcoholic steatohepatitis and non-small cell lung cancer. The drug candidate is formulated as hard capsules administered through oral route. It acts by targeting galectin 3.

Galecto overview

Galecto is a drug development company that includes the development of galectin modulators for the treatment of cancer, fibrosis and inflammation. The company develops activators and inhibitors of galectins. Its pipeline products include GB0139 to treat

For a complete picture of Selvigaltin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.